Clinical Trial Update: A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating subcutaneous blinatumomab in children with relapsed/refractory and MRD-positive B-cell precursor acute lymphoblastic leuke…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Precursor Acute Lymphoblastic Leukemia

Drugs mentioned

• BLINCYTO (BLINATUMOMAB)

Snippet

Sponsor: Amgen | Conditions: Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: RECRUITING